Literature DB >> 6180108

Antiretroviral effect of interferon: proposed mechanism.

R B Naso, Y H Wu, C A Edbauer.   

Abstract

Interferon (IFN) treatment of NIH Swiss mouse embryo cells chronically infected with Rauscher murine leukemia virus (R-MuLV) drastically reduced the release of virus particles from the cells. The characterization of intracellular and extracellular viral specific proteins and polyproteins immunologically with various antisera, and structurally by tryptic digest mapping experiments, indicated that the antiretroviral action of IFN was not due to an IFN-induced alteration in the synthesis of any viral protein. Steady state labeling experiments, however, showed that the processing of three viral specific precursor polyproteins, namely gPr90env, Pr40gag, and Pr25gag, were perceptively slowed in IFN-treated cells. This effect was apparently not related to the ability of these proteins to be modified by phosphorylation or glycosylation after translation since these processes occurred normally in the IFN-treated cells. The treatment of cells with IFN also caused the accumulation of a small amount of a fucosylated viral glycoprotein precursor, termed gP93env, in virus. With the exception of this minor protein, virus released from IFN-treated cells were normal in their content of viral proteins. These virus particles were only slightly less infectious, particle for particle, than virus released from control cultures. Based on these results, we suggest that IFN causes an as yet unelucidated alteration in cell membrane structure of function, or both, which prevents either the insertion of viral core precursor molecules into membrane or the recruitment or clustering of such viral polyproteins into virus assembly centers in the membrane. This suggested mechanism of IFN action is discussed in detail.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6180108     DOI: 10.1089/jir.1982.2.75

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  6 in total

1.  Biological activities of a synthetic peptide composed of two unlinked domains from a retroviral transmembrane protein sequence.

Authors:  D E Wegemer; K G Kabat; W S Kloetzer
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

2.  Differential antiviral effects of interferon in three murine cell lines.

Authors:  G C Sen; R E Herz
Journal:  J Virol       Date:  1983-03       Impact factor: 5.103

3.  Inhibition of human immunodeficiency virus type 1 morphogenesis in T cells by alpha interferon.

Authors:  M S Smith; R J Thresher; J S Pagano
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

4.  Early control of H5N1 influenza virus replication by the type I interferon response in mice.

Authors:  Kristy J Szretter; Shivaprakash Gangappa; Jessica A Belser; Hui Zeng; Hualan Chen; Yumiko Matsuoka; Suryaprakash Sambhara; David E Swayne; Terrence M Tumpey; Jacqueline M Katz
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

5.  Loss of infectivity by progeny virus from alpha interferon-treated human immunodeficiency virus type 1-infected T cells is associated with defective assembly of envelope gp120.

Authors:  B D Hansen; P L Nara; R K Maheshwari; G S Sidhu; J G Bernbaum; D Hoekzema; M S Meltzer; H E Gendelman
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

6.  Increase of cellular murine leukemia virus reverse transcriptase in interferon-treated cells.

Authors:  L W Mozes; D R Joseph
Journal:  Arch Virol       Date:  1984       Impact factor: 2.574

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.